GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » E10

SELLAS Life Sciences Group (FRA:RXK3) E10 : €-3,070.73 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

SELLAS Life Sciences Group's adjusted earnings per share data for the three months ended in Mar. 2024 was €-0.193. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-3,070.73 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 28.80% per year. During the past 5 years, the average E10 Growth Rate was 23.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of SELLAS Life Sciences Group was 28.80% per year. The lowest was 17.20% per year. And the median was 19.10% per year.

As of today (2024-06-19), SELLAS Life Sciences Group's current stock price is €1.014. SELLAS Life Sciences Group's E10 for the quarter that ended in Mar. 2024 was €-3,070.73. SELLAS Life Sciences Group's Shiller PE Ratio of today is .


SELLAS Life Sciences Group E10 Historical Data

The historical data trend for SELLAS Life Sciences Group's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group E10 Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10,486.00 -7,158.19 -7,218.10 -5,731.09 -3,024.02

SELLAS Life Sciences Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,374.37 -5,246.53 -5,136.80 -3,024.02 -3,070.73

Competitive Comparison of SELLAS Life Sciences Group's E10

For the Biotechnology subindustry, SELLAS Life Sciences Group's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Shiller PE Ratio falls into.



SELLAS Life Sciences Group E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SELLAS Life Sciences Group's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.193/131.7762*131.7762
=-0.193

Current CPI (Mar. 2024) = 131.7762.

SELLAS Life Sciences Group Quarterly Data

per share eps CPI Adj_EPS
201406 -3,753.637 100.560 -4,918.879
201409 -1,164.016 100.428 -1,527.362
201412 -1,459.816 99.070 -1,941.754
201503 -2,217.618 99.621 -2,933.407
201506 -2,673.027 100.684 -3,498.487
201509 -2,940.327 100.392 -3,859.541
201512 -3,304.837 99.792 -4,364.048
201603 -2,478.507 100.470 -3,250.791
201606 774.308 101.688 1,003.415
201609 -882.099 101.861 -1,141.160
201612 -696.787 101.863 -901.409
201703 -169.702 102.862 -217.404
201706 -200.250 103.349 -255.331
201709 -188.777 104.136 -238.884
201712 12.953 104.011 16.411
201803 -67.718 105.290 -84.753
201806 -53.928 106.317 -66.842
201809 -22.925 106.507 -28.364
201812 -26.584 105.998 -33.049
201903 -9.841 107.251 -12.091
201906 -5.602 108.070 -6.831
201909 -2.433 108.329 -2.960
201912 -1.314 108.420 -1.597
202003 -0.597 108.902 -0.722
202006 -0.586 108.767 -0.710
202009 -0.450 109.815 -0.540
202012 -0.230 109.897 -0.276
202103 -0.134 111.754 -0.158
202106 -0.249 114.631 -0.286
202109 -0.383 115.734 -0.436
202112 -0.372 117.630 -0.417
202203 -0.953 121.301 -1.035
202206 -0.388 125.017 -0.409
202209 -0.343 125.227 -0.361
202212 -0.406 125.222 -0.427
202303 -0.439 127.348 -0.454
202306 -0.286 128.729 -0.293
202309 -0.309 129.860 -0.314
202312 -0.229 129.419 -0.233
202403 -0.193 131.776 -0.193

Add all the adjusted EPS together and divide 10 will get our e10.


SELLAS Life Sciences Group  (FRA:RXK3) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


SELLAS Life Sciences Group E10 Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group (FRA:RXK3) Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group (FRA:RXK3) Headlines

No Headlines